We next investigated whether the beneficial effects of carvedilol on gluconeogenic enzymes, hepatic glucose production and muscular insulin signaling pathway were translated to the metabolic benefits of carvedilol treatment in HFD-induced obesity. The gene discussed is INS; the disease is obesity disorder.